Browsing Tag
Daratumumab
11 posts
J&J’s Talvey combination cuts the risk of death by up to 53% in earlier-line multiple myeloma
Johnson & Johnson (JNJ) Talvey combination cut the risk of death by up to 53% in earlier-line multiple myeloma, with FDA and EMA filings underway. Full analysis.
Is Dr. Reddy’s oncology pipeline strong enough to compete with global innovators in 2025 and beyond?
Explore Dr. Reddy’s oncology pipeline, biosimilars approvals, and revenue outlook—can the Hyderabad-based pharma firm compete with global cancer drug innovators?
Can Dr. Reddy’s build a biosimilars portfolio that rivals Biocon and global MNCs in regulated markets?
Explore Dr. Reddy’s biosimilars pipeline, regulatory milestones, and commercial strategy—can it compete with Biocon and global pharma giants in 2025?
GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as…
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…
Janssen Pharmaceutical’s DARZALEX FASPRO gains FDA approval for AL amyloidosis treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),…
Janssen seeks expanded approval for DARZALEX in treating AL amyloidosis
Janssen Pharmaceutical Companies of Johnson & Johnson has recently submitted a Type II variation application to the European…
Janssen, Amgen secure FDA approval for DKd regiment in multiple myeloma
DKd regiment FDA approval for multiple myeloma : Janssen Pharmaceutical Companies of Johnson & Johnson and Amgen have…
CANDOR clinical trial results : Amgen’s Kyprolis extends PFS in multiple myeloma patients
CANDOR clinical trial results : Amgen said that a phase 3 study assessing Kyprolis (carfilzomib) in combination with…
Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic
Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a…